Searchable abstracts of presentations at key conferences in endocrinology

ea0063oc12.5 | Endocrine Connections 2 | ECE2019

Sexual desire in transgender persons in relation with gender affirming hormone treatment: Results from ENIGI, a large multicenter prospective cohort study in transgender people

Defreyne Justine , Kreukels Baudewijntje , T'Sjoen Guyt , Heijer Martin Den , Heylens Gunter , Elaut Els

Background: The effect of testosterone on sexual arousal has been described in testosterone withdrawal and re-adminstration studies in birth-assigned males. In birth-assigned females, the relationship between sex steroids and sexual arousal is complex. Several steps in the transitioning process may affect sexual desire: hormone therapy (HT) and gender affirming surgery. HT in transgender men (TM) generally leads to increased sexual desire, masturbation frequency, sexual fantas...

ea0035p277 | Clinical case reports Thyroid/Others | ECE2014

When mother and daughter become father and son

Sajevets Tatjana , Verroken Charlotte , Heylens Gunter , Baere Elfride De , T'Sjoen Guy

Gender dysphoria (GD) leading to hormonal treatment and sex reassignment surgery that spans two generations has not been reported so far.The mother was diagnosed with GD at the age of 47. As an only child she suffered from emotional, physical, and sexual abuse by her parents. From the age of 3, she fantasized being a boy and started behaving like one. During later youth the genderdysphoric feelings were repressed. She married at the age of 18. One year l...

ea0032p682 | Neuroendocrinology | ECE2013

Hormonal therapy satisfaction is associated with better quality of life in transsexual persons

Wierckx Katrien , Geerts Lieselot , Anseeuw Edward , Motmans Joz , Elaut Els , Heylens Gunter , Decuypere Griet , T'Sjoen Guy

Introduction: Quality of life in transsexual persons after transition is among the most important outcome factors.Methods: A specialist center cross-sectional study in 193 transsexual women and 128 transsexual men (mean age 42.5 years) after on average 7.4 years of cross-sex hormone therapy and 6.6 years since sex reassignment surgery (SRS), compared to an age-and gender matched control population (1 to 3 matching). Self-reported physical and mental heal...

ea0032p969 | Steroid metabolism and action | ECE2013

Cross-sex hormone therapy related adverse events: data from a large gender identity unit

Wierckx Katrien , Anseeuw Edward , Geerts Lieselot , Elaut Els , Heylens Gunter , Motmans Joz , Decuypere Griet , T'Sjoen Guy

Introduction: Hormonal therapy is part of an established treatment of gender identity disorder, however outcome data regarding mortality and morbidity are scant.Methods: A specialist center cross-sectional study in 193 transsexual women and 128 transsexual men (mean age 42.5 years) assessing physical health and incidence of possible treatment related adverse events compared to an age-matched female and male control group recruited from a population study...

ea0056p667 | Neuroendocrinology | ECE2018

Does gender affirming hormone therapy affect anger proneness in transgender persons?

Defreyne Justine , Elaut Els , Kreukels Baudewijntje , Heylens Gunter , Schreiner Thomas , Fisher Alessandra Daphne , Heijer Martin Den , T'Sjoen Guy

Introduction: Anger is an emotional state of feelings varying from mild irritation to intense rage, whereas aggression implies externalizing angry emotions through destructive/ punitive behavior towards other persons/objects. Although research on the relationship between testosterone and aggression is inconclusive, the WPATH SOC 7 guidelines have warned for an increase in aggression in transgender men (TM) taking testosterone treatment.Aims:<p class=...